Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: Correlation with endothelial apoptosis, cytokine induction, and treatment outcome

Neoplasia

Volumn 9, Issue 2, 2007, Pages 128-135

  Seshadri, Mukund ^a   Spernyak, Joseph A ^a   Maier, Patricia G ^a   Cheney, Richard T ^a   Mazurchuk, Richard ^a   Bellnier, David A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

DMXAA; Multimodality imaging; Tumor necrosis factor ; Tumor vasculature; Vascular disrupting agents

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CD31 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; GADOLINIUM; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; COLON ADENOCARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRAVITAL MICROSCOPY; MICROSCOPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR BLOOD FLOW;

EID: 33847247311     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06748     Document Type: Article

References (32)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Less JR, Skalak TC, Sevick EM, and Jain RK (1991). Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51, 265-273.
3. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, and McDonald DM (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156, 1363-1380.
4. Boucher Y, Baxter LT, and Jain RK (1990). Interstitial pressure gradients in tissue isolated and subcutaneous tumors: implications for therapy. Cancer Res 50, 4478-4484.
5. Gillies RJ, Schornack PA, Secomb TW, and Raghunand N (1999). Causes and effects of heterogenous perfusion in tumors. Neoplasia 1, 197-207.
6. Denekamp J (1982). Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45, 136-139.
7. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5, 423-435.
8. Kelland LR (2005). Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 1, 1-9.
9. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, and Bellnier DA (2006). Activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 8, 534-542.
10. McDonald DM and Choyke PL (2003). Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725.
11. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, and Ching L (1999). Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59, 633-638.
12. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, and Baguley BC (2002). Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86, 1937-1942.
13. Baguley BC and Ching L-M (2002). DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54, 1503-1511.
14. Brattain MG, Stevens JS, Fine D, Webb M, and Sarrif AM (1980). Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 40, 2142-2146.
15. Wu NZ, Klitzman B, Dodge R, and Dewhirst MW (1992). Diminished leukocyte endothelium interaction in tumor microvessels. Cancer Res 52, 4265-4268.
16. Li C, Shan S, Huang Q, Braun R, Lanzen J, Hu K, Lin P, and Dewhirst M (2000). Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodents. J Natl Cancer Inst 92, 143-147.
17. Bogdanov AA Jr, Weissleder R, Frank H, Bogdanova AV, Nossiff N, Schaffer B, Tsai E, Papisov M, and Brady TJ (1993). A new macromolecule as a contrast agent for MR angiography: preparation, properties and animal studies. Radiology 187, 701-706.
18. Lewin M, Bredow S, Sergeyev N, Marecos E, Bogdanov A Jr, and Weissleder R (1999). In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int J Cancer 83, 798-802.
19. Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481.
20. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, and Matsuno S (1999). Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59, 1252-1258.
21. Zhao L, Ching LM, Kestell P, Kelland LR, and Baguley BC (2005). Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 116, 322-326.
22. McPhail LD, McIntyre DJO, Ludwig C, Kestell P, Griffiths JR, Kelland LR, and Robinson SP (2006). Rat tumor response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxy-indoleacetic acid levels and tumor necrosis. Neoplasia 8, 199-206.
23. Padhani A (2003). MRI for assessing antivascular cancer treatments. Br J Radiol 76, S60-S80.
24. Beauregard DA, Pedley RB, Hill SA, and Brindle KM (2002). Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15, 99-105.
25. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, and Padhani AR (2002). Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20, 3826-3840.
26. Kim YR, Yudina A, Figueiredo J, Reichardt W, Hu-Lowe D, Petrovsky A, Kang HW, Torres D, Mahmood U, Weissleder R, et al. (2005). Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res 65, 9253-9260.
27. Van Horssen R, ten Hagen TLM, and Eggermont AMM (2006). TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408.
28. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, and Urushizaki I (1988). Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48, 2179-2183.
29. Philpott M, Baguley BC, and Ching L-M (1995). Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36, 143-148.
30. Rainer GG (1996). Tumor necrosis factor-induced E-selectin expression on vascular endothelial cells. Crit Care Med 24, 1543-1546.
31. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MFX, and Alexander HR (2002). Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100, 1334-1339.
32. Seshadri M, Spernyak J, Bellnier D, and Mazurchuk R (2006). Multimodality imaging of vasculature in vivo. Soc Mol Imaging (Abstract 335).